Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

被引：5
|
作者：
Lim, Jonathan [1 ]
Samuelsen, Carl [2 ]
Golembesky, Amanda [2 ]
Shrestha, Sulena [3 ]
Wang, Li [3 ]
Griebsch, Ingolf [2 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] STATinMED Res, Plano, TX 75024 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 13期
关键词：
afatinib; EGFR tyrosine kinase inhibitors; erlotinib; first-line treatment; non-small-cell lung cancer; KINASE INHIBITOR-AFATINIB; HEALTH-CARE UTILIZATION; OPEN-LABEL; PHASE-III; REAL-WORLD; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE; TREATMENT PATTERNS; CHANNELING BIAS; GEFITINIB;
D O I：
10.2217/fon-2019-0052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Evaluate duration of therapy among patients treated with afatinib or erlotinib as first-line therapy for non-small-cell lung cancer (NSCLC). Materials & methods: NSCLC patients initiating afatinib or erlotinib between 2014 and 2017 were identified in three large claims databases in the USA. Propensity score matching was conducted to compare the duration of treatment between patients by treatment. Results: Patients prescribed afatinib had a significantly longer median duration of treatment compared with those prescribed erlotinib (12.1 vs 9.9 months; p = 0.035) and experienced a 14% reduction in risk of discontinuing therapy (adjusted hazard ratio: 0.86; CI: 0.75-0.99). Conclusion: First-line treatment duration in a real-world setting was significantly longer for patients prescribed afatinib compared with erlotinib.
引用
收藏
页码：1493 / 1504
页数：12
相关论文
共 50 条
  • [1] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [2] Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States
    Samuelsen, Carl
    Lim, Jonathan
    Golembesky, Amanda
    Shrestha, Sulena
    Wang, Li
    Griebsch, Ingolf
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 48 - 53
  • [3] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [4] Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
    Koehler, Jens
    Schuler, Martin
    ONKOLOGIE, 2013, 36 (09): : 510 - 518
  • [5] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [6] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    Park, Keunchil
    Bennouna, Jaafar
    Boyer, Michael
    Hida, Toyoaki
    Hirsh, Vera
    Kato, Terufumi
    Lug, Shun
    Mok, Tony
    Nakagawa, Kazuhiko
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Schuler, Martin
    Sibilotru, Denis Moro
    Tan, Eng-Huat
    Tanaka, Hiroshi
    We, Yi-Long
    Yang, James C-H
    Zhang, Li
    Zhou, Caicun
    Maerten, Angela
    Tang, Wenbo
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 132 : 126 - 131
  • [7] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [8] Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
    Laura Ortega-Granados, Ana
    Artal-Cortes, Angel
    Aguiar-Bujanda, David
    Oramas, Juana
    Luis Firvida, Jose
    De Castro, Javier
    Campillo Fuentes, Juana
    Gordo, Rocio
    Galan, Raquel
    Trigo, Jose
    ANTICANCER RESEARCH, 2019, 39 (03) : 1317 - 1328
  • [9] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
  • [10] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
12345